ACHROMYCIN Drug Patent Profile

Which patents cover Achromycin, and what generic alternatives are available?

Achromycin is a drug marketed by Lederle, Storz, and Avet. and is included in seven NDAs.

The generic ingredient in ACHROMYCIN is hydrocortisone; tetracycline hydrochloride. There are sixty-seven drug master file entries for this compound. Additional details are available on the hydrocortisone; tetracycline hydrochloride profile page.

Summary for ACHROMYCIN

US Patents:	0
Applicants:	3
NDAs:	7

US Patents and Regulatory Information for ACHROMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lederle	ACHROMYCIN	procaine hydrochloride; tetracycline hydrochloride	INJECTABLE;INJECTION	050276-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Storz	ACHROMYCIN	tetracycline hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	050268-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lederle	ACHROMYCIN	tetracycline hydrochloride	INJECTABLE;INJECTION	050273-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Avet	ACHROMYCIN V	tetracycline hydrochloride	CAPSULE;ORAL	050278-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Lederle	ACHROMYCIN	procaine hydrochloride; tetracycline hydrochloride	INJECTABLE;INJECTION	050276-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Achromycin Investment Analysis: Market Position, Patent Status, Generic Risk, and Commercial Outlook

Last updated: August 1, 2026

Achromycin is a legacy tetracycline brand with limited standalone investment value. Its active ingredient, tetracycline hydrochloride, is an old small-molecule antibiotic with no meaningful remaining composition-of-matter exclusivity. The commercial opportunity depends on manufacturing efficiency, distribution, product availability, and portfolio strategy rather than patent protection or clinical differentiation.

What is Achromycin and who markets it?

Achromycin is a brand name associated with tetracycline hydrochloride, an oral tetracycline-class antibiotic. The product has been marketed primarily as Achromycin V capsules and is used for susceptible bacterial infections, including respiratory, dermatologic, genitourinary, and certain sexually transmitted infections.[1]

Product attribute	Assessment
Brand	Achromycin V
Active ingredient	Tetracycline hydrochloride
Drug class	Tetracycline antibiotic
Dosage form	Oral capsules
Common strengths	250 mg and 500 mg historically listed
FDA pathway	Legacy approved prescription drug
Molecular status	Small molecule
Primary commercial issue	Generic substitution and supply economics
Patent position	No meaningful active basic-molecule patent protection
Biosimilar exposure	None
Standalone public revenue	Not separately reported

Historical FDA labeling identifies Achromycin V as a tetracycline hydrochloride product. Current commercial ownership and distribution can change through licensing, product transfers, or private-label arrangements. The brand should therefore be analyzed as a legacy product asset, not as a conventional branded pharmaceutical with an active research pipeline.

What patents protect Achromycin?

No active foundational patent is expected to protect Achromycin’s tetracycline hydrochloride molecule. Tetracycline was discovered and commercialized decades ago, placing the molecule well beyond the ordinary 20-year U.S. patent term under 35 U.S.C. §154.[2]

Does Achromycin have formulation patents?

The commercial product may have historical formulation, manufacturing, labeling, or process documentation, but these rights do not create a durable barrier comparable to a composition-of-matter patent. A standard immediate-release tetracycline hydrochloride capsule is generally vulnerable to generic competition because a competing manufacturer can reproduce the active ingredient and dosage form under the Abbreviated New Drug Application pathway.

Any remaining formulation protection would have to be assessed at the specific product and patent-listing level. The commercial importance of that protection is limited because:

1. Tetracycline hydrochloride is an established active ingredient.
2. Immediate-release capsules are technically straightforward relative to complex injectables or modified-release products.
3. Generic manufacturers can use alternative excipients or manufacturing processes.
4. FDA approval of a therapeutically equivalent generic can support pharmacy-level substitution where state law permits.

Are method-of-use patents relevant to Achromycin?

Method-of-use patents are unlikely to provide material protection for Achromycin. The label covers established antibiotic indications rather than a newly discovered indication, biomarker-defined population, or proprietary treatment regimen. Any historical use patents would generally have expired or would not prevent generic entry for the nonprotected indications.

When does Achromycin lose exclusivity?

Achromycin’s meaningful market exclusivity ended decades ago. The relevant loss of exclusivity did not arise from a recent patent expiration. It resulted from the age of tetracycline hydrochloride, the availability of generic tetracycline products, and the absence of a modern exclusivity platform.

Exclusivity category	Achromycin position
New chemical entity exclusivity	Expired decades ago
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current relevance
New clinical investigation exclusivity	No known current basis
Composition-of-matter patent	Expired
Formulation patent	No demonstrated durable barrier
Method-of-use patent	No demonstrated current barrier
Generic competition	Established

The relevant investment question is not whether Achromycin will lose exclusivity. It already operates in a post-exclusivity market. The question is whether the brand can retain a price or distribution advantage over generic tetracycline hydrochloride.

What is the FDA and Orange Book status of Achromycin?

Achromycin is associated with a legacy FDA-approved tetracycline hydrochloride product. The FDA’s Orange Book identifies approved drug products and, where applicable, therapeutic-equivalence information and listed patents.[3]

For an investment assessment, the following points matter:

• Achromycin is not a biologic and does not use the biosimilar pathway.
• A generic competitor would generally pursue an ANDA, not a 505(b)(2) application, if it duplicates the established dosage form and route.
• Any current Orange Book listing must be checked against the specific NDA holder and product entry.
• The absence of an active listed patent would reduce the probability of a patent-based delay to generic approval.
• Drug approval and commercial availability are separate issues. A product can remain FDA-approved while having intermittent distribution or limited pharmacy presence.

Are there Paragraph IV challenges to Achromycin?

A Paragraph IV challenge is unlikely to be commercially significant because Achromycin’s core exclusivity has expired and tetracycline hydrochloride has long been available as a generic product. Paragraph IV litigation typically matters when a generic applicant challenges an unexpired listed patent. That fact pattern does not fit a legacy tetracycline capsule unless a specific, unexpired formulation or use patent is listed.

No material current Paragraph IV event is central to the Achromycin investment case based on the product’s established generic status.

How strong is the Achromycin patent estate?

The patent estate is weak from an investment perspective.

Patent factor	Investment assessment
Basic molecule	No current protection
Core clinical uses	Broadly genericized
Immediate-release capsule	Low barrier to replication
Manufacturing process	Potentially protectable but usually avoidable
Device or delivery system	Not material for standard capsules
Pediatric or orphan exclusivity	No apparent current value
Litigation leverage	Low
Generic entry deterrence	Low

Manufacturing know-how can still have commercial value. Tetracycline products require controls for stability, impurity profiles, packaging, and supply consistency. Those factors may affect product quality and cost, but they do not normally prevent a capable generic manufacturer from entering the market.

What generic entry risks exist for Achromycin?

Generic substitution is the central risk. Tetracycline hydrochloride is an established generic antibiotic, and pharmacies, wholesalers, hospitals, and government purchasers typically prioritize price, availability, and contract terms.

The principal risks are:

Price erosion

A branded legacy product must either accept generic-level pricing or justify a premium through availability, authorized-generic status, contracting, or brand recognition. Tetracycline has limited differentiation that would support sustained premium pricing.

Contract concentration

A small number of wholesalers, pharmacy chains, or institutional buyers can exert substantial pressure on net price. Loss of a distribution agreement can reduce sales quickly.

Supply substitution

Prescribers and pharmacists may substitute among tetracycline-class products where clinically appropriate. Doxycycline, minocycline, and other tetracycline derivatives may also compete for certain indications, even though they are not direct pharmaceutical equivalents.

Regulatory and quality risk

Legacy antibiotics can be affected by manufacturing deviations, shortage events, import restrictions, and changes in active pharmaceutical ingredient supply. A single-source manufacturing arrangement increases exposure to production interruptions.

How does Achromycin compare with doxycycline and minocycline?

Achromycin competes in a broader tetracycline market, but the comparison must distinguish direct generic substitution from therapeutic substitution.

Product	Active ingredient	Commercial position	Relative investment risk
Achromycin V	Tetracycline hydrochloride	Legacy branded or distributed product	High generic and pricing risk
Generic tetracycline	Tetracycline hydrochloride	Direct equivalent competition	Low differentiation
Doxycycline	Doxycycline hyclate or monohydrate	Widely used, broader contemporary prescribing base	Stronger demand profile
Minocycline	Minocycline hydrochloride	Dermatology and other indications	More differentiated use profile
Newer tetracycline derivatives	Varies	Indication-specific or resistant-infection focus	Potentially stronger IP

Doxycycline is often commercially stronger because of its broad use in acne, respiratory infections, tick-borne disease, sexually transmitted infections, and other indications. Achromycin’s principal advantage is historical recognition and, in some periods, possible availability in situations where other tetracycline products face supply constraints.

What is the revenue exposure from Achromycin?

Achromycin revenue is not generally disclosed as a separate line item by a diversified pharmaceutical company. That prevents a conventional product-level valuation based on reported sales, gross margin, or prescription growth.

The economic value of the product is more likely to arise from:

• Contribution margin within a generic or specialty portfolio.
• Distribution rights or private-label arrangements.
• Manufacturing utilization.
• Portfolio bundling with other antibiotics.
• Temporary supply shortages affecting competing products.
• Institutional contracts requiring a recognized product source.

A buyer should not assign a blockbuster-style revenue multiple to Achromycin. A defensible valuation would use a low-growth, high-competition framework based on net sales, gross margin, supply reliability, and remaining commercial rights.

Which companies are challenging Achromycin?

The principal competitive pressure comes from manufacturers of generic tetracycline hydrochloride rather than from a branded challenger. Generic competition can include manufacturers with ANDA approvals, contract manufacturers, and private-label distributors.

The competitive landscape should be evaluated using:

1. FDA Orange Book therapeutic-equivalence entries.
2. Current FDA drug-shortage records.
3. Wholesale acquisition cost and actual acquisition cost data.
4. National Drug Code activity.
5. Pharmacy and hospital formulary status.
6. Product discontinuation and reactivation notices.

The number of approved generic applicants does not equal the number of active suppliers. Some approved products have limited distribution or are not commercially marketed.

What patent litigation and settlements affect Achromycin?

Achromycin is unlikely to be affected by a current patent-settlement structure of the type seen in protected branded drugs. With no apparent high-value active patent estate, there is limited basis for a reverse-payment agreement or delayed generic-entry settlement.

The more relevant legal issues are commercial:

• Trademark ownership and brand-use rights.
• Product-transfer agreements.
• Manufacturing and supply contracts.
• FDA compliance.
• Product-liability claims.
• Distribution exclusivity.
• Antitrust exposure if a distributor controls supply.

Trademark rights may protect the Achromycin name, but trademark protection does not prevent sale of therapeutically equivalent tetracycline under a generic name.

What manufacturing and intellectual-property barriers exist?

Manufacturing is a moderate operational barrier but a weak intellectual-property barrier. A supplier must maintain:

• Consistent tetracycline hydrochloride potency.
• Control of degradation products and impurities.
• Appropriate moisture and light protection.
• Validated capsule-filling processes.
• cGMP compliance.
• Reliable API sourcing.
• Packaging that preserves stability through shelf life.

These requirements can eliminate poorly qualified suppliers, but they do not establish durable exclusivity. The strongest commercial moat would come from a reliable low-cost supply chain, not from patents.

What are the likely investment scenarios for Achromycin?

Base case: low-growth legacy product

Achromycin remains commercially available as a niche or portfolio product. Sales are stable or decline gradually, pricing remains constrained, and value comes from supply reliability and modest contribution margins.

Upside case: shortage-driven demand

A supply disruption affecting generic tetracycline or competing antibiotics creates temporary demand for Achromycin. The benefit would likely be episodic. It would not establish durable pricing power unless the supplier could maintain availability over an extended period.

Downside case: discontinuation or substitution

The product loses distribution, manufacturing becomes uneconomic, or prescribers shift toward doxycycline and minocycline. Revenue falls toward residual demand, and the brand becomes an administrative asset rather than a growth product.

Strategic-acquisition case

A private company acquires Achromycin as part of a broader portfolio of established products. The value would be based on cash generation, manufacturing synergies, and channel access. The brand alone would not normally justify a high strategic premium.

Key Takeaways

• Achromycin is a legacy tetracycline hydrochloride brand with no meaningful current composition-of-matter exclusivity.
• Its market is exposed to established generic competition and pharmacy-level substitution.
• Formulation, method-of-use, and manufacturing rights provide limited practical protection for a standard immediate-release capsule.
• Paragraph IV litigation and patent settlements are unlikely to drive the investment thesis.
• The product is not subject to biosimilar competition.
• Revenue is not separately reported, making product-level valuation dependent on private operating data.
• The strongest commercial assets are supply reliability, distribution access, and manufacturing economics.
• The base investment case is low-growth and cash-flow oriented, not innovation driven.
• Upside depends mainly on shortages, portfolio synergies, or acquisition value rather than on patent expansion.

FAQs About Achromycin Investment and Patent Risk

Is Achromycin still a branded drug?

Achromycin is a legacy brand associated with tetracycline hydrochloride. Its current commercial availability and marketing entity can vary by product listing, distributor, and market.

Can a generic manufacturer copy Achromycin?

A generic manufacturer can generally develop an equivalent tetracycline hydrochloride capsule through the ANDA pathway, subject to FDA approval, bioequivalence, manufacturing, and labeling requirements.

Does Achromycin have biosimilar competition?

No. Tetracycline hydrochloride is a small molecule, so competitors use the generic-drug framework rather than the biosimilar pathway.

Is Achromycin a good acquisition target?

It may be suitable as a low-cost portfolio acquisition where the buyer has manufacturing or distribution synergies. Its limited patent protection and generic competition argue against a high standalone valuation.

What would increase Achromycin’s commercial value?

Higher value would require durable supply scarcity, an exclusive distribution position, manufacturing cost advantages, or inclusion in a broader portfolio that produces measurable selling and administrative synergies.

References

1. U.S. National Library of Medicine. (n.d.). Achromycin V: Tetracycline hydrochloride capsule, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
2. United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights. https://uscode.house.gov/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files/